T1D Fund: A Breakthrough T1D Venture

The T1D Fund is a venture capital firm focused on accelerating life-changing solutions for Type 1 Diabetes (T1D) by investing in mission-driven companies developing therapies to treat, prevent, and cure T1D. Established in 2016 as an independently run subsidiary of Breakthrough T1D, the fund addresses the lack of private investment in T1D, aiming to bridge the gap between scientific advancements and the delivery of solutions to those affected by the disease. With over $200 million in assets under management, the T1D Fund is the largest disease-focused venture impact fund globally, investing in a diverse portfolio of companies across the prevention, treatment, and cure spectrum.

The fund's investment strategy emphasizes impact over ownership, leveraging valuable relationships within Breakthrough T1D’s network of clinicians, regulators, and donors to enable success for its portfolio companies. By reinvesting any realized gains into new investments, the T1D Fund demonstrates its commitment to its mission of curing T1D. The fund has made 45 investments to date, with multiple successful company exits ranging from trade sales to big pharma and IPOs. Notably, in November 2022, one of the fund’s investee companies, Provention Bio, received the first FDA approval for a disease-modifying therapy in T1D (TZIELD).

The T1D Fund operates on a unique evergreen model: donor-funded to support investments in for-profit entities, with exit proceeds recycled back into the fund. This approach allows the fund to attract and deploy capital to advance promising disease-modifying therapies and provide cures for those living with T1D. By strategically aligning with Breakthrough T1D, the leading global T1D research and advocacy organization, the fund focuses exclusively on supporting innovative approaches and novel mechanisms with curative potential. The T1D Fund continues to support companies that play a role in the discovery and therapeutic development of effective solutions to T1D, aiming to transform the therapeutic landscape of the disease through its investment approach.